Effects of Topically Applied Betulinic Acid and NVX-207 on Melanocytic Tumors in 18 Horses.
Authors: Weber Lisa A, Delarocque Julien, Feige Karsten, Kietzmann Manfred, Kalbitz Jutta, Meißner Jessica, Paschke Reinhard, Cavalleri Jessika-M V
Journal: Animals : an open access journal from MDPI
Summary
# Editorial Summary: Topical Betulinic Acid for Equine Melanoma Melanoma represents a significant welfare concern in grey horses, particularly Lipizzaners, yet treatment options remain limited. Researchers investigated whether two naturally occurring compounds—betulinic acid (BA) and its synthetic derivative NVX-207—could reduce tumour burden when applied topically twice daily for 91 days to early-stage cutaneous melanomas in 18 mares across three treatment groups (placebo, 1% BA, and 1% NVX-207). Topical BA application produced statistically significant tumour volume reduction compared to placebo from day 80 onwards, whilst NVX-207 showed a trend towards reduction that did not achieve statistical significance; importantly, both treatments demonstrated excellent safety profiles with no systemic adverse effects detected on clinical examination or haematological analysis. Although these results are encouraging and the practical convenience of topical application is advantageous for field practitioners, the small cohort size and preliminary nature of the findings mean this protocol cannot yet be routinely recommended—replication in a larger population with improved pharmaceutical formulations is essential before clinical adoption. The study nevertheless provides valuable proof-of-concept that topical BA warrants further development as a non-invasive therapeutic option for managing early melanocytic lesions in predisposed breeds.
Read the full abstract on PubMed
Practical Takeaways
- •Betulinic acid shows promise as a topical treatment for early-stage equine cutaneous melanoma, with significant tumor reduction observed by day 80, but this remains experimental and not yet recommended for routine clinical use.
- •The current formulation and treatment protocol require optimization and larger-scale validation before practitioners should consider adopting this approach in their practice.
- •Topical application is convenient and safe, making it a non-invasive option worth monitoring for future development, though practitioners should continue using established melanoma management strategies.
Key Findings
- •Betulinic acid (BA) significantly reduced melanoma tumor volume compared to placebo from day 80 onwards in topical application.
- •NVX-207 showed a trend toward tumor volume reduction but did not reach statistical significance.
- •Topical treatment with both BA and NVX-207 was well-tolerated with no reported safety concerns over 91 days.
- •Limited sample size (18 horses in 3 groups) and preliminary nature of findings necessitate replication in larger cohorts before clinical recommendation.